Key Points
- Halozyme CEO Helen Torley sold 60,000 shares across transactions from Feb. 3 to Mar. 4 (including 10,000 on Mar. 4 at $70.21), totaling about $4.40 million and lowering her stake by 1.29% to 767,780 shares valued at roughly $53.9 million.
- The company posted a surprise quarterly EPS of -$0.24 vs. $1.92 expected, though revenue beat at $451.8 million (up 51.6% YoY); analysts' consensus is a "Hold" with an average price target of $78.56.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $70.21, for a total value of $702,100.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company's stock, valued at $53,905,833.80. This represents a 1.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.
Helen Torley also recently made the following trade(s):
- On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $1,393,800.00.
- On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $78.64, for a total value of $786,400.00.
- On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $76.12, for a total transaction of $1,522,400.00.
Halozyme Therapeutics Trading Up 0.9%
Shares of Halozyme Therapeutics stock opened at $70.02 on Thursday. Halozyme Therapeutics, Inc. has a 52-week low of $47.50 and a 52-week high of $82.22. The firm has a market capitalization of $8.26 billion, a PE ratio of 28.12, a price-to-earnings-growth ratio of 0.28 and a beta of 0.98. The company has a debt-to-equity ratio of 43.89, a current ratio of 4.66 and a quick ratio of 3.66. The company's fifty day moving average price is $72.71 and its two-hundred day moving average price is $70.76.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. During the same period in the previous year, the business posted $1.26 earnings per share. Halozyme Therapeutics's revenue was up 51.6% on a year-over-year basis. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.
Institutional Trading of Halozyme Therapeutics
Several large investors have recently made changes to their positions in the business. Root Financial Partners LLC bought a new position in shares of Halozyme Therapeutics in the third quarter valued at about $25,000. Measured Wealth Private Client Group LLC increased its position in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 124 shares in the last quarter. Larson Financial Group LLC increased its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 343 shares in the last quarter. Richardson Financial Services Inc. raised its stake in shares of Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 198 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $32,000. Institutional investors own 97.79% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on HALO shares. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. TD Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 19th. The Goldman Sachs Group restated a "sell" rating and issued a $56.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Finally, Weiss Ratings lowered shares of Halozyme Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $78.56.
Check Out Our Latest Report on Halozyme Therapeutics
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
